Interested in what Capua BioServices has to offer in the field of microbial process development & manufacturing?
Want to win a cuddly Giant Microbe? Want to taste some Italian Aperitivi & Snacks? Then please do stop by booth 1D81 during CPhI Madrid!
Alora, this year Capua BioServices is exhibiting at CPhI and is exited to meet you there! Come find us at 1D81 to learn all about our latest news. During recent months we have been completing expansions in our laboratory, spray-drying facility as well our dedicated GMP and food-grade manufacturing suites.
Capua BioServices is focused on fermentation. We understand that microbial expression technology is not a solution for all, but for selected products, microbial fermentation does provide several advantages over cell culture. The microbial processes are typically much shorter, less complex and therefor can be more economically attractive. We are also convinced the microbial manufacturing technology is here to stay. Recent trend reports in biopharmaceutical manufacturing show that the overall trend towards outsourcing will continue to increase in size and complexity. This combined with the shift in ratio of mammalian/microbial in manufacturing from 54%/41% in 2003 79%/48% in 2018 shows that mammalian is on the rise, and microbial will remain.
Capua BioServices continues to strengthen its process development capabilities as enabler to manufacturing. We are dedicated to manufacturing and dedicated to our clients. The investments made during the past 3 years in our people, processes and plant allow us to keep flexibility while adding value to our strategic partnerships. In the end people buy from people, we are convinced that it are our people in our plant that make the different; they turn their experience into custom solutions.
As our current service portfolio is based on already 60 years of experience in microbial manufacturing, we truly believe that people, expertise and dedication are the key to success in the strategic partnerships we enter into. Come and check out the Pharma Insight Briefing on Tuesday October 9, 14.30 by Elise Mous. She will highlight some key recent examples and case studies on how the company has been able to develop into the microbial contract development and manufacturing organization it is today.
